Avidian Wealth Enterprises’s Biogen BIIB Stock Holding History

Avidian Wealth Enterprises’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,008	Closed	-$234K	–	504
2024 Q2	$234K	Buy	1,008 +78	+8%	+$17K	0.01%	449
2024 Q1	$201K	Sell	930 -457	-33%	-$107K	0.01%	428
2023 Q4	$359K	Buy	1,387 +75	+6%	+$18.4K	0.02%	313
2023 Q3	$337K	Sell	1,312 -2,092	-61%	-$560K	0.02%	311
2023 Q2	$970K	Buy	3,404 +41	+1%	+$12.2K	0.06%	182
2023 Q1	$935K	Sell	3,363 -29	-0.9%	-$8.02K	0.05%	209
2022 Q4	$939K	Sell	3,392 -528	-13%	-$149K	0.06%	187
2022 Q3	$1.05M	Buy	3,920 +937	+31%	+$199K	0.08%	143
2022 Q2	$608K	Buy	2,983 +358	+14%	+$73.2K	0.04%	237
2022 Q1	$553K	Buy	2,625 +660	+34%	+$144K	0.03%	281
2021 Q4	$471K	Buy	1,965 +17	+0.9%	+$4.37K	0.03%	315
2021 Q3	$551K	Buy	1,948 +392	+25%	+$128K	0.04%	201
2021 Q2	$539K	Buy	1,556 +155	+11%	+$47K	0.04%	207
2021 Q1	$392K	Buy	1,401 +86	+7%	+$23.2K	0.03%	245
2020 Q4	$322K	Buy	+1,315	New	+$339K	0.03%	248

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Avidian Wealth Enterprises's BIIB Position: Q3 2024 in Review

Avidian Wealth Enterprises sold out of Biogen (BIIB) in Q3 2024, closing a stake of 1,008 shares — an estimated $234K sold.

Avidian Wealth Enterprises first reported a position in BIIB in Q4 2020 and held it in 15 quarters. The position peaked at $1.05M in Q3 2022. 917 funds tracked by Wall St. Rank hold BIIB as of Q3 2024.

Avidian Wealth Enterprises reported no remaining Biogen position as of Q3 2024 after selling out during the quarter.
Avidian Wealth Enterprises sold 1,008 Biogen shares in Q3 2024, an estimated $234K.
Avidian Wealth Enterprises first reported a position in Biogen in Q4 2020 and held it in 15 quarters.
Avidian Wealth Enterprises's Biogen position peaked at $1.05M in Q3 2022.
917 funds tracked by Wall St. Rank held Biogen as of Q3 2024.

Based on Avidian Wealth Enterprises's 13F filing for Q3 2024, filed 30 Oct 2024.